Upstream Bio (UPB) Free Cash Flow (2023 - 2026)

Upstream Bio's Free Cash Flow history runs 4 years deep, the most recent figure standing at -$47.9 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 16.24% year-over-year to -$47.9 million; the TTM figure through Mar 2026 stood at -$140.1 million (down 68.46% YoY), while the FY2025 annual figure was -$133.4 million, down 123.58% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$47.9 million, down from -$30.7 million in the prior quarter.
• The five-year high for Free Cash Flow was -$8.0 million in Q2 2024, with the low at -$47.9 million in Q1 2026.
• The 4-year median for Free Cash Flow is -$21.1 million (2024), against an average of -$25.7 million.
• The sharpest annual moves came in 2025 and 2026: Free Cash Flow tumbled 388.29% in 2025, then fell 16.24% in 2026.
• Upstream Bio's Free Cash Flow stood at -$16.1 million in 2023, then decreased by 24.08% to -$20.0 million in 2024, then tumbled by 53.78% to -$30.7 million in 2025, then sank by 55.66% to -$47.9 million in 2026.
• Business Quant data shows UPB's Free Cash Flow at -$47.9 million in Q1 2026, -$30.7 million in Q4 2025, and -$22.2 million in Q3 2025.